Skip to main content
Figure 2 | Cardiovascular Diabetology

Figure 2

From: Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome

Figure 2

Individual levels of A) glucose disposal rate, B) adiponectin, C) fasting plasma insulin, and D) fasting plasma glucose in monkeys given aleglitazar 0.03 mg/kg per day. The final day of dosing at 0.03 mg/kg per day aleglitazar (labeled in the figures as day 42), due to scheduling needs, ranged across monkeys from 44 to 46 days.

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840